Lonza to buy US biologics site from Roche for US$ 1.2 billion
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
More than 10,000 scientific publications containing EUDRAGIT
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Cureskin aims to disrupt the large and growing skin and hair care industry in India
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Anand is committed to leading the company's continued commitment to driving innovation in Health Care through the utilization of Digital transformation, AI and LLM
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
Subscribe To Our Newsletter & Stay Updated